BioCardia granted Japanese patent for Helix biotherapeutic delivery catheter expiring 2034

BioCardia, Inc.

Japan Patent Office issued Patent No. 7641330 titled 'Radial and Transendocardial Delivery Catheter'.
Patent term expires on or after September 30, 2034; covers helical needle-tipped catheter platform.
BioCardia CEO cites growing IP position for cell/gene therapy delivery; Japan is important initial market.
Helix System is the only catheter-based intramyocardial delivery system in active clinical use per BioCardia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.